The mechanisms underlying resistance to trastuzumab often involve alterations in HER2 expression, activation of alternative signaling pathways, and changes in tumor microenvironment, which can be potentially countered through optimized re-challenge strategies. The gene discussed is ERBB2; the disease is neoplasm.